Kodiak Sciences Inc.

Clinical-stage biotech developing long-acting therapies for retinal eye diseases

What Kodiak Sciences does

Kodiak Sciences is a biopharmaceutical company focused on treatments for chronic, blinding retinal diseases such as wet age-related macular degeneration and diabetic eye disease. Its approach aims to make injectable eye therapies last longer between doses, reducing the frequent injections patients otherwise need.

How Kodiak Sciences makes money

As a clinical-stage biotech, Kodiak currently has little or no product revenue; it is funded by capital raised from investors and spends on research and clinical trials. Its future value depends on getting its lead candidates through trials and regulatory approval, after which it would earn revenue by selling — or partnering to sell — approved therapies.

Products & services

• retinal disease pipeline (wet AMD, diabetic eye disease)
• ABC (Antibody Biopolymer Conjugate) platform
• clinical-stage eye therapies